Admin Control Panel

New Post | Settings | Change Layout | Edit HTML | Edit posts | Sign Out


March20 podcast Dr Hazen
anti-TMA pill in a year or 2 ? (scroll 12 mins)

Additional info:
MEBO Karen
at UK Findacure conf 2020

Scroll down and select country

MEBO Map Testing & Meetups

Full details :
want listed ? contact

MEBO - UBIOME study 2018



MEBO Gut Microbiome Study
"Microbial Basis of Systemic Malodor and PATM Conditions (PATM)"
Funded by uBiome Research Grant

"Microbial Basis of Systemic Malodor and PATM Conditions (PATM)"

Dynamics of the Gut Microbiota in
Idiopathic Malodor Production

Started May 2018 - Ongoing

Current people sent kits : 100/100
3 kits per person


Participation info : LINK English

MEBO Private Facebook Group
to join : go to
or contact
Join/Watch the weekly
BO Sufferers Podcasts



TMAU Petition world
TMAU UK end total:262
TMAU UK ends 23/01/20
TMAU Petition USA end total 204
USA : Moveon open
TMAU (Dominican)
Metabolomic Profiling Study

Start : Aug 2016
Stage 1 : 27 Canadian volunteers to test
Latest click here (26 oct) :
17 samples returned

Note : Stage 1 is Canada only.
Return cut-off date : passed
Analysis can take 6/8 weeks
Analysis start in/before Nov
MEBO Research is a
NORD Member Organization
See RareConnect TMAU

Popular Posts (last 30 days)

Upcoming get-togethers

Let us know if you want a meetup listed
Follow MeBOResearch on Twitter

Blog Archive

Denver TMAU Test Lab survey click here
click to Read more/less

USA survey for anyone who wants to improve Denver TMAU test

begun : Dec22
end : no ending for now

A trainee genetic counselor is working at the Denver TMAU test lab. Probably as part of her training. As a project she wishes feedback on any aspect of the Denver TMAU test and process. You can fill in the survey and/or email her (email address is in survey). It's meant for USA people, but perhaps others can give their view too (as we have so few opportunities).

quote from her rareconnect post

"Hello all! I wanted to make you aware of a research study being conducted to better understand the experience and needs of individuals with trimethylaminuria with a goal of being able to create improved patient and healthcare provider education materials. Any participation is completely voluntary and all responses remain confidential. Feel free to use the contact information within the link with any questions or share the survey with others with TMAU."

see this post for more details

Monday, June 14, 2021

Lauching MEBO COVID-19 Back-To-Normal Clinical Trial


Survey in English
eConsent in English
Survey en español
Conentimiento electrónico en español

See above-noted documents for privacy commitments

Our MEBO Scientific Director and Founder of Aurametrix, Irene Gabashvili, PhD., has developed and registered a Clinical Trial sponsored by MEBO Research, including MEBO US, MEBO UK, and MEBO Africa, with the collaboration of Aurametrix. The Application and (Protocol #20210103MEBO) Narrative with all applicable attachments were approved by the MEBO Research Institutional Review Board (IRB). This study is supported by both, the Office of Human Research Protections (OHRP) and the US Food and Drug Administration (FDA), as well as the Office for Civil Rights.

This study raises the question about the effects of COVID vaccines on people with odor conditions worldwide compared to people who don’t have odor conditions. It not only looks for intensity levels of odor symptoms, but also for other short-term and long-term reactions, i.e., skin rashes, greater fatigue than prior to the vaccine, intensity levels and increase in allergic reaction, immune reactions, neurological symptoms, such as tingling sensations, muscle cramping, headaches, etc., and how they compare to the general population that does not suffer from odor conditions. If there are differences, it might open the window to further research in hopes to better understand whether these difference can lead us to a greater understanding of odor conditions in general.

As noted in the site, Detailed Description of the "COVID-19 Back-to-Normal Study,"

Detailed Description: The outbreak of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) was declared a Public Health Emergency of International Concern in January 2020 and upgraded to pandemic in March 2020. First vaccines to prevent COVID-19 were authorized for emergency use in the US in December 2020, but a number of unknowns still remains. One of these unknowns is the relationship of the microbiota, gut dysbiosis and impaired metabolism with active immunity to pathogens and vaccines and tolerance to antigens. Study groups will be based on age, metabolism and self-reported symptoms. Data will be collected continuously via surveys and investigator-participant interactions, as needed. Statistical methods used will be the ones with the greatest power.

Why is this study significant for the MEBO community?

Since 2009, the 4 Clinical Trials that MEBO has carried out has addressed the microbial basis of systemic malodor and PATM conditions, explored the relationships between malodor and urine metabolomes as well as volatile organic compounds in alveolar breath, which may shed some light on the relationship of the microbiota, gut dysbiosis and impaired metabolism with immunity to pathogens and vaccines and tolerance to antigens.

Comparing comminalities and differences in the data between sufferers and persons who do not suffer from odor conditions/PATM might give our experts a greater understanding of why some people have a greater tendency towards having an odor condition than others. Perhaps the experts might be able to more clearly identify what contributes to or causes some odor conditions.

your participation is entirely voluntary and you have the right to withdraw at any time throughout this process, as noted in the eConsent.
The study is estimating to enroll 1,000 participants, and we hope to include a significant number of MEBO participants to be able to acquire a stronger based data on how sufferers of odor conditions/PATM reacted to any and all COVID-19 vaccines, compared to non-sufferers. Please participate by asking for a MEBO ID# from to proceed to take the 16 question survey in English or in Spanish.

What outcomes will be measured:

Primary Outcome Measures :
1. Adverse reactions/events [ Time Frame: 10 days post-doses 1 and 2 ]
Percentage of occurrence, types, duration and severity of adverse events occurring within 10 days post-doses 1 and 2

Secondary Outcome Measures :

1. Long-term adverse events [ Time Frame: Throughout the study period, until 12 months post-final-dose ]
Percentage of occurrence, types, duration and severity of adverse events throughout study period
2. Percentage of participants with COVID-19 Disease [ Time Frame: From 14 days after completion of the 2-dose regimen up to 12 months post-final-dose ]

Please note that your participation is entirely voluntary and you have the right to withdraw at any time throughout this process, as noted in the eConsent. The more people in our community from around the world volunteer to take part in this study, the more data our scientists will have at their disposal to more effectively carry out research that we hope someday will provide us with one or more treatment options, and someday, hopefully, a cure.

get New Posts by EMAIL : Enter your email address :


María de la Torre
Founder and Executive Director

A Public Charity
MEBO's Blog (English)
El Blog de MEBO (español)

A EURORDIS and NORD Member Organization


Unknown said...

Estoy dispuesto a participar siempre y cuando no se revele mi identidad.
También deberían de alentar a todos los de la comunidad que sufren de diferentes tipo de malos olores a participar para que haya más resultados de este ensayo clínico, entre más personas participen es mejor,estés mi punto de vista, también hace falta que nos dirijan para tratar de hacer algún tipo de conciencia al mundo sobre este tipo de henfermedad

Jun 15, 2021, 8:12:00 PM
Maria de la Torre said...

Gracias por tu comentario. La máxima prioridad de este ensayo es proteger la privacidad de cada participante. Consulte el Consentimiento electrónico para obtener más detalles al respecto.
y el Protocolo #20210103MEBO.

Thank you for your comment. The utmost priority of this study is to protect the privacy of each participant. Please refer to the eConsent, and Protol #20210103MEBO for further details.

Jun 20, 2021, 12:05:00 PM
Post a Comment